Related Experiment Videos
Opiate properties of SKF 525A
Canadian Journal of Physiology and Pharmacology
|August 1, 1978
Summary
SKF 525A, an inhibitor of drug-metabolizing enzymes, exhibits opiate-like effects. While less potent than methadone in assays and animal studies, its analgesic properties were confirmed and blocked by naloxone.
Area of Science:
- Pharmacology
- Neuroscience
- Drug Metabolism
Background:
- SKF 525A is a known inhibitor of microsomal drug-metabolizing enzymes.
- Its chemical structure resembles diphenylpropylamine analgesics.
- Observed effects in animals suggest potential interactions with opiate systems.
Purpose of the Study:
- To investigate the opiate receptor binding affinity of SKF 525A.
- To compare the analgesic potency of SKF 525A with methadone in animal models.
- To determine if the analgesic effects of SKF 525A are mediated by opiate receptors.
Main Methods:
- Opiate radioreceptor assay to determine binding affinity.
- Hot plate test in mice to assess analgesia.
- Intracerebroventricular administration in rats to evaluate central analgesic effects.
- Naloxone pretreatment in mice to block opiate receptors.
Main Results:
- SKF 525A showed significantly lower potency than methadone in opiate radioreceptor assays, with a notable sodium-dependent effect.
- In mice, SKF 525A produced less analgesia than methadone on a hot plate.
- Pretreatment with naloxone abolished the analgesic effect of SKF 525A in mice.
- SKF 525A demonstrated analgesic properties when administered intracerebroventricularly in rats.
Conclusions:
- SKF 525A possesses less opiate agonist character compared to methadone.
- The analgesic effects of SKF 525A are mediated through opiate receptors.
- SKF 525A exhibits central analgesic activity.